日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Correction: Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy

更正：意大利溃疡性结肠炎一线治疗方案中维多珠单抗与阿达木单抗治疗方案的成本效益比较

期刊:Pharmacoeconomics-Open
影响因子:2.1
doi:10.1007/s41669-025-00596-w
Salcedo, Jonathan; Hill-McManus, Daniel; Hardern, Chloë; Opeifa, Oyin; Viti, Raffaella; Siviero, Ludovica; Roscini, Antonio Saverio; Di Martino, Gennaro
肠炎
结肠炎
发表日期：2025
文献求助 收藏

Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy

在意大利，维多珠单抗作为一线高级疗法与阿达木单抗治疗方案在溃疡性结肠炎治疗中的成本效益比较

期刊:Pharmacoeconomics-Open
影响因子:2.1
doi:10.1007/s41669-024-00497-4
Salcedo, Jonathan; Hill-McManus, Daniel; Hardern, Chloë; Opeifa, Oyin; Viti, Raffaella; Siviero, Ludovica; Roscini, Antonio Saverio; Di Martino, Gennaro
结肠炎
肠炎
发表日期：2024
文献求助 收藏

An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective

关注公平性：从英国社会视角出发，运用分配成本效益分析法瑞西单抗改善糖尿病性黄斑水肿患者的健康公平性

期刊:
影响因子:
doi:10.1038/s41433-024-03043-y
Meunier, Aurelie; Opeifa, Oyin; Longworth, Louise; Cox, Oliver; Bührer, Christian; Durand-Zaleski, Isabelle; Kelly, Simon P; Gale, Richard P
糖尿病
代谢
发表日期：2024
文献求助 收藏